Table of Contents

Definition

3D bioprinting is an additive manufacturing technology that dispenses cell-laden biomaterials under computer control to construct complex, three-dimensional, functional living tissues or artificial organs¹. The technology belongs to the additive manufacturing process family defined in ISO/ASTM 52900:2021, which establishes the international vocabulary for building physical three-dimensional geometries by the successive addition of material².

Its biological basis is the bioink: a solution of one or more biomaterials in hydrogel form, usually encapsulating the desired living cell types, that is crosslinked or stabilized during or immediately after printing to generate the intended shape, structure, and architecture of the designed construct³. The technology models the native tissue microenvironment, including organ-level geometry, spatially organized multicellular composition, an extracellular-matrix-like matrix, and the cell-cell and cell-matrix interactions that monolayer culture cannot reproduce^{1 3}.

Structurally, bioink is deposited layer by layer as droplets, filaments, or photocrosslinked planes in accordance with a digital design; crosslinking chemistry, whether ionic, thermal, or photopolymerization, stabilizes each layer; embedded cells subsequently attach, remodel the surrounding matrix, and mature toward tissue-like organization^{1 3}. Across bioprinting approaches, feature resolutions span approximately 10 to 1,000 μm¹.

Purpose

The primary value proposition of 3D bioprinting is automated, reproducible, on-demand fabrication of living constructs with precise control over geometry, cell placement, and material patterning, amenable to high-throughput production³.

The technology is motivated by two unmet needs. In regenerative medicine, bioprinting is regarded as a versatile fabrication technique that may address the growing organ shortage¹; in the United States alone, approximately 109,800 candidates were on the national transplant waiting list, twelve people die each day awaiting an organ, and a new candidate joins the list every seven minutes⁴. In biomedical research, bioprinting provides human-relevant tissue models for research, drug discovery, and toxicology^{1 5}.

Bioprinting improves upon legacy models in both domains. Historically, drug screening relied on simple two-dimensional cell cultures and animal models, whose limited ability to predict human drug responses has driven the development of more precise alternatives⁶. Bioprinted tissues are constructed from human cells and present native-like three-dimensional architecture, thereby bridging the interspecies differences and incomplete human physiology that weaken animal-model extrapolation⁶. Given drug development costs estimated at approximately 2.6 billion US dollars per approved therapy⁵, gains in preclinical predictive validity carry substantial economic and ethical significance. Bioprinting further enables personalized disease models generated from patient-derived cells for patient-specific drug discovery and therapeutic planning⁵.

Methodology

The standard workflow proceeds from clinical imaging or computer-aided design data, which are processed into machine instructions; the bioink is then formulated, the construct is printed layer by layer, the structure is stabilized by crosslinking, and the construct is matured in culture before evaluation^{1 3}.

Four principal printing modalities are recognized¹:

• Inkjet: droplet ejection driven by thermal or piezoelectric actuation.
• Extrusion: pneumatic or mechanical dispensing of continuous filaments.
• Laser-assisted: nozzle-free, laser-induced forward transfer of bioink droplets.
• Stereolithography and digital light processing: selective photopolymerization of bioinks in a vat.

Substrates are hydrogel-based bioinks formulated from natural polymers, such as alginate, collagen, gelatin and its methacrylate derivative GelMA, and Matrigel, and from synthetic polymers such as PEGDA and PEGDMA, employed alone or as hybrid materials^{1 3}. Growth factors and other biomolecules can be incorporated into the bioink and therefore into the developed construct⁶. Gelation strategies, including ionic crosslinking, thermal gelation, and photopolymerization, are matched to the demands of each modality^{1 3}. Perfusable vascular networks may be introduced during fabrication; vat-polymerization approaches have produced multivascular networks with open perfusable channels of approximately 300 μm within PEGDA/GelMA constructs printed with light-absorbing bioink additives⁷.

Instrumentation comprises sterile, cell-compatible bioprinter platforms with modality-specific operating windows. Inkjet heads require low-viscosity bioinks of approximately 3.5 to 12 mPa·s and tolerate only modest cell densities; extrusion systems accommodate viscosities from 30 mPa·s to above 6 × 10⁷ mPa·s and the highest cell densities, including cell spheroids; and stereolithography imposes essentially no viscosity limitation¹.

Performance

Comparative reviews report the following empirical operating characteristics^{1 7}:

Modality	Cell viability	Print speed	Supported viscosity	Resolution
Inkjet	Above 85%, typically 80 to 90%	Fast	3.5 to 12 mPa·s	High
Laser-assisted	Above 95%	Medium	1 to 300 mPa·s	High
Extrusion	40 to 80%	Slow	30 mPa·s to above 6 × 10⁷ mPa·s	Moderate; typically above 100 μm
Stereolithography/DLP	Above 85%	Fast	No limitation	High; up to approximately 10 μm

Stereolithography resolution can reach approximately 10 μm by reducing the laser spot size⁷, and laser-induced forward transfer achieves micron-level resolution with high cell survival and no risk of nozzle clogging⁸. With respect to reproducibility, automated deposition confers reproducibility and precise control over fabricated constructs³; among the modalities, nozzle-free laser-based printing generates the most reproducible constructs, although it is difficult to adjust and control⁶.

Current technical boundaries remain substantial. High-resolution cell deposition, controlled cell distributions, vascularization, and innervation within complex three-dimensional tissues are unresolved challenges¹. Extrusion is slow, and associated shear stress limits cell viability to 40 to 80%¹; inkjet printing is restricted to low-viscosity, low-cell-density bioinks¹; and laser-assisted systems are expensive and complex, which limits adoption¹. Bioprinting inherits its terminology from the standardized additive manufacturing vocabulary of ISO/ASTM 52900², yet bioprinting-specific performance standards and regulatory criteria are still maturing, and international regulatory harmonization is considered critical for the acceptance of bioprinted drug-testing models⁶.

Applications

Primary research applications include regenerative medicine and tissue engineering, in which transplantable skin, cartilage, and bone constructs have been demonstrated¹; disease modeling, in which bioprinted cancer models, including a breast cancer model with stromal compartmentation that remained viable for approximately 14 days, have been applied to hormonal agents and chemotherapeutics such as paclitaxel and tamoxifen⁵; and high-throughput predictive drug screening and toxicology¹.

Industrial applications concentrate on pharmaceutical drug screening, dermatological and cosmetic testing of bioprinted skin models, and personalized disease models for patient-specific drug discovery and therapeutic planning⁵.

Standardized contexts of use are in vitro drug testing in which human-cell composition, three-dimensional architecture, and reproducible automation are decisive; bioprinted models are positioned to bridge the interspecies differences and poor clinical predictivity of legacy preclinical models⁶.

Deployment remains predominantly at the research and preclinical in vitro stage. Regulatory frameworks for bioprinted drug-testing models are still under development, and continuous evaluation of their performance and safety is required for wider regulatory acceptance⁶.

Variations

• Inkjet Bioprinting: Droplet-based ejection of low-viscosity bioinks driven by thermal or piezoelectric actuators; a low-cost, rapid, high-resolution modality restricted to modest cell densities, with viability typically between 80 and 90%¹.
• Extrusion Bioprinting: Pneumatic or mechanical dispensing of continuous filaments; offers the widest range of materials, viscosities, and cell densities, including cell spheroids, at moderate resolution and lower print speed^{1 7}.
• Laser-Assisted Bioprinting: Nozzle-free laser-induced forward transfer of bioink droplets, first applied to cell printing in 2004; provides micron-level resolution, cell viability above 95%, and compatibility with viscous, high-cell-density bioinks, offset by cost and operational complexity⁸.
• Stereolithography-Based Bioprinting: Selective photopolymerization of bioinks by laser or projected light; enables rapid fabrication, resolutions approaching 10 μm, and no viscosity limitation, constrained by photoinitiator compatibility and light dosimetry^{1 7}.